中韩高清无专码区2021曰_色翁荡熄又大又硬又粗又视频图片_波多野结衣乳巨码无在线观看_国产91福利在线播放_国产人妻人伦精品_马来西亚潜水天堂_黄色免费网站下载_免费看黄网站黄污污污热门软件_小莹客厅激情46章至50章视频

Jiangsu Xinrui Pharmaceutical Co., Ltd. was established in March 2012 as a major investment promotion project in Nantong City. In 2016, it was selected for the National Development and Reform Commission's major project repository for supply-side structural reforms. The company is located in the Rugao Port Chemical New Materials Industrial Park in Rugao City, Jiangsu Province. It specializes in the production of active pharmaceutical ingredients (APIs) and intermediates for conditions such as hypertension, hyperlipidemia, and hyperglycemia, as well as advanced chemical intermediates. The company emphasizes independent research and development, collaborative innovation, and possesses multiple independent intellectual property rights along with approvals for Class 1 new drugs.

The company has a registered capital of 153.6956 million yuan and has invested over 200 million yuan to date. The factory site covers an area of 88,342.8 square meters, with production workshops spanning more than 50,000 square meters. It includes Class A and B warehouses covering 3,000 square meters and Class C workshops and warehouses covering 14,000 square meters. The waste treatment area occupies over 10,000 square meters, with more than 20 million yuan invested in environmental protection equipment. The on-site wastewater treatment station is designed to handle 1,000 cubic meters per day, meeting current operational needs while allowing room for future expansion. The facilities are designed and constructed in compliance with FDA requirements, featuring GMP workshops, advanced analytical and product laboratories, and a comprehensive quality assurance system. The company holds 17 nationally authorized invention patents and operates multiple production lines, including an automated line for 550 tons of Valsartan per year, as well as lines for 100 tons of Rosuvastatin Calcium, 500 tons of 4-Fluoro-3-phenoxybenzaldehyde, and 500 tons of 3,3-Dimethylbutyryl chloride, among others. Forty percent of its products are exported to Europe and the United States, demonstrating strong expertise and brand influence.

Xinrui Pharmaceutical's philosophy is "Focus on technological innovation to achieve public well-being." The company is committed to addressing major societal health needs through independent innovation, clean production, and green development, aiming to build a high-end pharmaceutical innovation base that creates value for society and contributes to public welfare.